BRAF Alterations in Chronic Lymphocytic Leukemia: Genomic Landscape, Co-Mutation Patterns, and Clinical Relevance
Current Hematologic Malignancy Reports · 01.05.2026 · 21 (1)
DOI: 10.1007/s11899-026-00780-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Hematologic Malignancy Reports, online erschienen am 01.05.2026. Verfasst von Abdulrahman Al-Abdulmalek und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, McGill University Health Centre, Montreal, QC, H4A 3J1, Canada. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Leukemia, Lymphocytic, Chronic, B-Cell, Biomarkers, Tumor, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hamad Medical Corporation.
Abstract (Originalsprache)
Purpose of Review BRAF alterations are uncommon in chronic lymphocytic leukemia (CLL), yet increasing use of broad genomic profiling has identified them as a recurrent component of MAPK-pathway dysregulation. This revised review summarizes the reported frequency, mutation spectrum, co-mutation patterns, treatment-era associations, and clinical implications of BRAF alterations in adult CLL, with explicit separation of chemoimmunotherapy-dominant cohorts from targeted-therapy-era cohorts. Recent Findings Across published studies, BRAF mutations are usually detected in approximately 2–6% of unselected CLL cohorts, with higher frequencies in biologically enriched or treatment-selected populations. In chemoimmunotherapy-dominant cohorts, the clinically relevant signals are more often seen in treatment-timing endpoints such as time to first treatment, treatment-free survival, or time to next treatment than in overall survival alone. In targeted-therapy-era studies, including phase II and real-world cohorts, BRAF alterations recur as part of MAPK-pathway–driven clonal evolution at relapse after BTK-, PI3K-, or BCL2-directed therapy. Small pathology-based series also suggest that BRAF V600E is more frequent in Richter transformation than in untransformed CLL. By contrast, direct evidence for BRAF inhibitors in CLL is very limited, and available preclinical data do not support routine single-agent BRAF inhibition for the predominantly non-V600E lesions seen in CLL. Summary Current evidence supports interpreting BRAF-mutated CLL within the broader RAS–RAF–MAPK–ERK signaling context rather than as a classical V600E-driven entity. At present, BRAF is best viewed as a biologic and resistance-relevant annotation rather than an established standalone prognostic biomarker or routine therapeutic target. Its clinical relevance appears greatest in trisomy 12-enriched disease, genomically complex cases, Richter transformation with V600E lesions, and treatment-exposed relapse where pathway-directed strategies may become increasingly important.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, McGill University Health Centre, Montreal, QC, H4A 3J1, Canada.
- Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, H4A 3J1, Canada.
- Department of Hematology, National Center for Cancer Care and Research, Doha, Qatar. mmohammed35@hamad.qa.
- Department of Hematology, National Center for Cancer Care and Research, Doha, Qatar.
- College of Medicine, Qatar University, Doha, Qatar.
- Internal Medicine Department, University of Missouri, Columbia, Missour, 65211, USA.
Förderung
- Hamad Medical Corporation
Zitieren
APA
Al-Abdulmalek, A., Landry, E., Abdulgayoom, M., Al-Mashdali, A. F., Dalol, A. A., Muthanna, B., Routy, J. P., & Mohamed, S. F. (2026). BRAF Alterations in Chronic Lymphocytic Leukemia: Genomic Landscape, Co-Mutation Patterns, and Clinical Relevance. Current Hematologic Malignancy Reports, 21(1). https://doi.org/10.1007/s11899-026-00780-7
Vancouver
Al-Abdulmalek A, Landry E, Abdulgayoom M, Al-Mashdali AF, Dalol AA, Muthanna B, et al. BRAF Alterations in Chronic Lymphocytic Leukemia: Genomic Landscape, Co-Mutation Patterns, and Clinical Relevance. Current Hematologic Malignancy Reports. 2026;21(1). doi:10.1007/s11899-026-00780-7
BibTeX
@article{AlAbdulmalek2026,
author = {Al-Abdulmalek, Abdulrahman and Landry, Eric and Abdulgayoom, Mohammed and Al-Mashdali, Abdulrahman F and Dalol, Ayman Abdullah and Muthanna, Bassam and Routy, Jean-Pierre and Mohamed, Shehab F},
title = {BRAF Alterations in Chronic Lymphocytic Leukemia: Genomic Landscape, Co-Mutation Patterns, and Clinical Relevance},
journal = {Current Hematologic Malignancy Reports},
year = {2026},
volume = {21},
number = {1},
doi = {10.1007/s11899-026-00780-7}
}
EUVIMED